ADVERUM Trademark

Trademark Overview

On Monday, July 25, 2016, a trademark application was filed for ADVERUM with the United States Patent and Trademark Office. The USPTO has given the ADVERUM trademark a serial number of 79194977. The federal status of this trademark filing is SECTION 71 ACCEPTED as of Wednesday, July 3, 2024. This trademark is owned by Adverum Biotechnologies, Inc.. The ADVERUM trademark is filed in the Pharmaceutical Products category with the following description:

Gene therapy pharmaceutical preparations; pharmaceutical preparations for gene therapy for the treatment of genetic diseases or disorders; pharmaceutical preparations for use in the treatment of gene therapy treatable diseases
adverum

General Information

Serial Number79194977
Word MarkADVERUM
Filing DateMonday, July 25, 2016
Status706 - SECTION 71 ACCEPTED
Status DateWednesday, July 3, 2024
Registration Number5303797
Registration DateTuesday, October 10, 2017
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 25, 2017

Trademark Statements

Goods and ServicesGene therapy pharmaceutical preparations; pharmaceutical preparations for gene therapy for the treatment of genetic diseases or disorders; pharmaceutical preparations for use in the treatment of gene therapy treatable diseases

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, November 1, 2016
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameAdverum Biotechnologies, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressUS
Party NameAdverum Biotechnologies, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressMenlo Park CA 94025
US
Party NameAdverum Biotechnologies, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressMenlo Park CA 94025
US

Trademark Events

Event DateEvent Description
Friday, November 4, 2016ASSIGNED TO EXAMINER
Thursday, October 27, 2016SN ASSIGNED FOR SECT 66A APPL FROM IB
Tuesday, November 1, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, November 4, 2016NON-FINAL ACTION WRITTEN
Saturday, November 5, 2016APPLICATION FILING RECEIPT MAILED
Saturday, November 5, 2016NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Thursday, November 10, 2016REFUSAL PROCESSED BY MPU
Thursday, November 10, 2016NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Friday, November 25, 2016REFUSAL PROCESSED BY IB
Wednesday, May 10, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, June 2, 2017ASSIGNED TO LIE
Thursday, June 8, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, June 8, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, June 14, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, June 20, 2017LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, July 5, 2017NOTICE OF PUBLICATION
Tuesday, July 25, 2017PUBLISHED FOR OPPOSITION
Friday, August 18, 2017TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, August 18, 2017ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, September 14, 2017TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, October 10, 2017REGISTERED-PRINCIPAL REGISTER
Wednesday, January 10, 2018FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Saturday, January 20, 2018FINAL DISPOSITION PROCESSED
Saturday, January 20, 2018FINAL DISPOSITION NOTICE SENT TO IB
Friday, February 16, 2018FINAL DECISION TRANSACTION PROCESSED BY IB
Monday, October 10, 2022COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Friday, January 20, 2023NEW REPRESENTATIVE AT IB RECEIVED
Saturday, February 4, 2023CHANGE OF NAME/ADDRESS REC'D FROM IB
Friday, September 29, 2023TEAS SECTION 71 RECEIVED
Wednesday, July 3, 2024REGISTERED-SEC.71 ACCEPTED
Wednesday, July 3, 2024NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
Tuesday, May 21, 2024CASE ASSIGNED TO POST REGISTRATION PARALEGAL

Related Keywords

adverum gene preparations pharmaceutical therapy diseases treatment treatable disorders genetic